FIG. 3.

In vivo efficacy against S. aureus ATCC 29213 (year 2005) at a low inoculum (4.13 log₁₀ CFU per thigh when subcutaneous treatment q1h started), after some makers of generics acquired manufacturing secrets from Eli Lilly. Vancomycin generic products were compared with the innovator (VAN-Lilly) in dose-effect experiments (18.75 to 300 mg/kg per day) using the neutropenic mouse thigh infection model (each data point represents the mean CFU/g of both thighs from a single mouse). VAN-Abbott France, VAN-Baxter, and VAN-Lilly fitted to the Hill model and were indistinguishable (P = 0.7681). VAN-Proclin, on the other hand, displayed again the Eagle effect, fitting the Gaussian instead of the Hill model, as happened before 2005.